With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.
Helen H. Moon, MD, principal investigator with the Cancer Clinical Trials Access Program in the Southern California Permanente Medical Group, research lead for melanoma, regional medical oncology lead for genitourinary cancer, and hematologist/oncologist at Kaiser Permanante Riverside Medical Center, discusses the usefulness of tivozanib (Fotivda) for patients with recurrent clear cell renal cell carcinoma (ccRCC) in the third-line setting.
The efficacy and safety data of this therapy is from the phase 3 TIVO-3 trial (NCT02627963), which randomly assigned patients who had failed 2 or 3 systemic lines of therapy to tivozanib versus sorafenib (Nexavar).
The trial showed that patients receiving tivozanib had a higher median progression-free survival of 5.6 months versus 3.9 months for patients on sorafenib (HR 0.73; 95% CI, 0.56-0.94; P = .016). Moreover, at the time of the primary analysis, the objective response rate was 18% among patients given the tyrosine kinase inhibitor (TKI) compared with 8% for patients given sorafenib.
According to Moon, this demonstrates the impact this therapy can have in the third-line setting for patients who failed several lines of therapy prior. Compared with therapies in the first line setting for patients with ccRCC, there has yet to be as effective treatments for patients experiencing recurrent disease. Now, with tivozanib showing no new safety signals—except for hypertension, which Moon explains is a class effect of TKIs— there is now another option to consider for these heavily pretreated patients.
Transcription:
0:08 | We're increasingly getting patients, when they get to the third line, having already been exposed to both TKI and immunotherapy. And so, what we have left as they enter into that place in treatment is [that] they're looking for effective treatment with increasing awareness of the adverse event profile and tivozanib really fits quite well into that space.
0:35 | There are preclinical data, [and now] certainly with the results of TIVO-3, it really indicates a highly effective therapy and a very potent blocker of the [VEGF pathway] and that compared to sorafenib, which is a representative TKI of that first generation, it is better.
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen